(Progress of Disclosed Matters)

First Dosing of F573 Phase I Clinical Trial in China

January 20, 2022 – GNI Group Ltd., (TSE Mothers listed code: 2160) today announced the first dosing of the F573 Phase I clinical trial at Wuhan Xiehe Hospital of Huazhong University of Science and Technology. The purpose of the study is to understand the safety and pharmacokinetics of F573 in human.

F573 is a small molecule dipeptide compound, which is a broad-spectrum covalent inhibitor of cysteine-specific cleaved caspase family (Caspase). It has shown excellent efficacy and safety in various animal liver failure modeling experiments and can significantly improve animal survival. It is approved by China NMPA for clinical trials involving liver failure patients. F573 and F351 represent Beijing Continent's commitment to find new therapy for unmet medical needs of liver disease patients.

Liver failure is a syndrome characterized by severe impairment of liver function due to massive necrosis/apoptosis of liver cells. It is divided into four categories: acute liver failure (ALF), subacute liver failure, acute-on-chronic (subacute) liver failure (ACLF) and chronic liver failure, which can be seriously life-threatening. At present, the only effective clinical treatment method is liver transplantation, but there is a lack of donor sources, and there is an urgent need for effective treatment drugs.

For further inquiries
URL: www.gnipharma.com
Email: infojapan@gnipharma.com